The future of translational manufacturing is here - TRI is building Australia’s first scale-up biomedical manufacturing facility for maturing, high-potential, biotech start-ups.

TM@TRI (Translational Manufacturing@TRI) is proudly funded by the Queensland Government and TRI.

Timeline

* Future timeline projections are subject to change

The TRI facility gives early-phase start up biotech companies time to establish, build, test and develop their products and provides a supportive environment to advance medical discoveries to healthcare solutions. In response to the lack of scale-up manufacturing facilities in Australia, TRI has secured funding to build Translational Manufacturing@TRI (TM@TRI), Australia’s first scale-up biomedical manufacturing facility supporting mid-stage biotech companies as they mature and manufacture products for Phase II and III clinical trials studies.

TM@TRI is being developed in response to market demand and aspiration from tenant start-ups outgrowing or “scaling up” out of the original TRI and a need to remain within its supportive environment as they continue their commercialisation journey. 

TM@TRI will add 6,484m² Gross Floor Area to TRI’s 38,390m² GFA, making this the largest end to end translational research hub of its kind in Australia.

TM@TRI will be operated by TRI and will leverage the research strengths and clinical synergies of its four shareholder partners: Queensland Health, The University of Queensland, the Queensland University of Technology and Mater Research.

TM@TRI Facilities & Services 

• Co-working desk spaces and offices, including meeting rooms and pitch spaces
• An Innovation space to support engineering and chemistry
• Kitchen and open-plan communal spaces designed to facilitate interation and collaboration 
• Access to all the services, support and facilities already housed in TRI
• Access to clinicians and clinical trial facilities and expertise
• Permitted PC2 laboratories 
• Fridge, Freezer and Cryo storage farms that are monitored, secured and alarmed 
• Storage space and specialist support spaces for pre-post manufacturing
• GMP cleanrooms and manufacturing facilities 
  • 6 cleanrooms with independent air handling, reducing contamination risks
  • ISO 7 (GradeB) capable rooms – up to ISO 5 (Grade A) using barrier technology
  • PC2 regulatory compliant construction – available for GMOs and viral genetic medicine
  • cGMP autoclave
  • Sterile processing with continuous particle monitoring (fully validated, 21CFR part 11 and PIC/S (Annex 11) compliant Environmental Monitoring System (EMS)
• 24/7 critical systems monitoring, on-site security, swipe card restricted access to all rooms
• Waste management
• Hands on training and specialist support.

Early Construction Works 

TM@TRI will be situated on the PA Hospital campus between PACE, Thermo Fisher and TRI. It sits within the Boggo Road Cross River Rail Priority Development Area (PDA), which is focused on health, science, innovation, research and education.

Early works on the TM@TRI site commenced in July and were paused after the discovery of asbestos on site. 

In line with the Queensland Work Health and Safety Regulation 2011 and WorkSafe Queensland, our contractor Built engaged a team of experts to undertake additional site testing and develop an Asbestos Removal Control Plan.

On Wednesday 20 September, Built, and asbestos removal experts Corvex and HazSure, will commence remediation of the site working under an approved Asbestos Removal Control Plan. These works will likely run until the end of the year. 

Based on the information we have been provided by Built, we understand that works will be conducted in accordance with certain codes and regulations including the following:

• Work Health and Safety Act 2011 (Qld);
• Environmental Protection Act 1994 (Qld);
• WHS Regulations;
• Environmental Protection Regulation 2008 (Qld);
• Workplace Health and Safety Queensland (WHSQ) “How to safely remove asbestos” Code of Practice 2021; and
• WHSQ "Scaffolding" Code of Practice 2009.

We understand that dust suppression protocols and daily air particle monitoring will also be in place across the site. All works are being monitored by a licensed asbestos assessor and hygienist, who is responsible for notifying the relevant authorities and TRI, if particles reach a level deemed unsafe by WorkSafe Queensland. Works will stop if there are any safety concerns.  Traffic and pedestrian management plans are also in place on Kent Street.

Where can I find out more about TM@TRI?

Built has been contracted to deliver early construction works for TM@TRI. Project related queries can be directed to James Dane at Built on 0400 956 086 or [email protected] and site related queries to Chris Woodforth on 0423 559 614.

Our TM@TRI Project Team is also happy to answer any queries you may have. Email contact: [email protected] or [email protected].  Regular updates will be provided on our website. We thank you for your patience and ongoing support as we progress our goal to build a facility capable of transforming biomedicine in Australia.